One-fifth of Zantac 75 U.S. sales came "at the expense" of Rx Zantac, Glaxo tells analysts.
This article was originally published in The Tan Sheet
ONE-FIFTH OF ZANTAC 75 SALES CAME "AT THE EXPENSE" OF Rx ZANTAC, Glaxo Wellcome CEO Richard Sykes told securities analysts in New York City on Aug. 1. Commenting on the "success of Zantac 75," Sykes noted that the H2 antagonist is "rapidly going past Tagamet HB [and] approaching now the level of Pepcid AC." However, Sykes noted, "some of that growth has come at the expense of prescription Zantac sales."
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning